Webinar - The UK’s cancer burden: What employees and employers need to know
13 February 2025
A 40-min webinar for HR professionals and Line Managers, in partnership with Check4Cancer, a leading early cancer detection company and one of Generali UK’s Wellbeing Investment Matching partners.
About this event
The UK has one of the worst cancer survival rates in developed countries, and worst in the G7. Education, prevention and rapid diagnostic cancer pathways are all key to tackling this. But public sector overwhelm, characterised by lack of investment in the clinicians, the tools and the technology, have left experts to predict a tsunami of cancers by 2040.
Professor Gordon Wishart, CEO and Chief Medical Officer of Check4Cancer, joins us to:
- Explore the UK and global cancer burden
- Understand the impact on private medical insurance
- Discuss why and how 40% of all cancers are preventable
- Learn what early cancer detection looks like, and how employers can help.
Register
To register please click here.
This 40-min webinar will take place on Thurs 13th Feb 2025, at 11:00hrs and will be hosted on Zoom.
If you would like to submit a question for our expert speakers, please do so via email to eb.enquiries@generali.co.uk no later than Friday 7th Feb 2025.
A recording will be made available to all registered attendees after the event.
Expert Speakers
Professor Gordon Wishart MBChB MA (Cantab.) MD FRCS (Eng.) FRCS (Gen.)
Professor Gordon Wishart is the former Director of the Cambridge Breast Unit from 2005-2010, and current Visiting Professor of Cancer Surgery at Anglia Ruskin University since 2008. He has a strong track record in clinical research, with more than 100 peer-reviewed papers in scientific journals. In 2010 he led a team of clinicians and scientists that developed the PREDICT breast cancer treatment and survival model, now used worldwide.
Professor Wishart is also the founder, CEO & Chief Medical Officer of Cambridge-based Check4Cancer, a leading early cancer detection company. In 2016 Check4Cancer launched rapid access, streamlined and audited diagnostic pathways for breast and skin cancer to the insured and self-pay markets, leading to the award of “Diagnostic Provider of the Year” at the annual Health Investor Awards in 2018. Check4Cancer has recently developed cancer risk assessment and impact models that underpin risk-stratified cancer screening programmes, with education and behavioural change at the centre of a cancer prevention strategy, resulting in the 2022 Laing Buisson “Innovation in Health Tech” award for the MyCancerRisk programme.
Stay in touch
Keep informed about Generali products & services, events, wellbeing calendar updates and more.
Sign up and select your preferences using this link.